Safety and Preliminary Performance of Xtrac O.S. System for Lead Extraction.

Bradycardia Clinical Trial

— XTR  

Official title:

First in Man, Open-label, Multi Center Safety and Preliminary Performance of Xtrac O.S. System for Lead Extraction.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06115980
• Other study ID #: XTR-01-0322
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 27, 2023
• Est. completion date: July 20, 2024

Study information

• Verified date: April 2023
• Source: Xtrac O.S.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, interventional, feasibility, prospective, multicenter, clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.

A total of 15 patients, who are scheduled for CIED lead extraction, will be recruited in order to ensure a total of at least 10 patients finishing the study procedures and follow up.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: July 20, 2024
• Est. primary completion date: May 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Men or Female patients, 18-85 years old.

2. Patients must understand the procedures and methods of this study and be willing to sign the informed consent form and to complete the trial in strict accordance with clinical trial protocol.

3. Scheduled for a CIED lead extraction upon current guidelines.

4. Lead implant duration more than 1 year and less than 5 years.

5. Patient must be SARS-CoV-2 negative and without Covid-19 signs and symptoms, prior to enrollment.

6. Patients are classified as ASA II/III.

7. Leads with external diameter of 7Fr-9Fr.

Exclusion Criteria:

1. Patient age > 85 years old.

2. Hemodynamic instability.

3. Class IV NYHA heart failure.

4. Contrast allergy.

5. Patients felt to be high risk due to degree of acute illness or systemic comorbidities.

6. Patients who are placed on a heparin bridge, and are felt to be high risk for even brief discontinuation of anticoagulation

7. Pregnant or lactating.

8. Participating in another clinical study.

Eligibility will be determined by the PI and investigators based on the exclusion/inclusion criteria, current medical status and evaluation of the procedure risks mitigation.

Related Conditions & MeSH terms

• Bradycardia

Intervention

Device:
• lead extraction (Xtrac O.S. system)
This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach. The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA). Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction. A multidisciplinary team evaluation involving cardiac surgery, electrophysiologist, and cardiac anesthesiology should allow for a rapid and successful response to major complications

Locations

Country	Name	City	State
Israel	Hadassah Medical Center	Jerusalem

Sponsors (3)

Lead Sponsor	Collaborator
Xtrac O.S.	KCRI, Scopus Research

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate safety related to the lead extraction procedure, or the extraction tool	To collect and evaluate device- and procedure-related adverse events.	0 to 30 days post-lead extraction
Secondary	To assess the ease of use, duration of the procedure and the physician satisfaction by questions by a Likert scale	Using Likert scale (1 - Poor; 2 - Fair; 3 - Good; 4 - Excellent)	During procedure
Secondary	To evaluate the rate of complete procedural success of removal leads implanted for more than 1and up to 5 years	Complete procedural success is the removal of the targeted lead and all lead material from the vascular space, with the absence of permanently disabling complications or procedure-related death	Acute setting (during the surgical procedure)
Secondary	To evaluate the rate of clinical procedural success	Clinical procedural success is the removal of all targeted leads and all lead material from the vascular space, or retention of a small portion of the lead (fragment that is 4 cm or smaller) that does not negatively impact the outcome goals of the procedure	Acute setting (during the surgical procedure)